SecBot SecBot
PRESS-RELEASE ·Filed Nov 15, 2026

DRTS

Alpha Tau Medical Ltd.
BULLISH
Impact 7/10
Horizonweeks Processed1d 11h ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Monitor upcoming scans for confirmation of responses and differentiation between necrosis and tumor progression; watch for enrollment completion and any regulatory submission discussions. The conference call on November 16 may provide additional detail on the path to market.

DirectionBullish
Confidencehigh
Horizonweeks

Alpha DaRT

▲ Bullish Named in this press release
Impact
Phase
Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
Time to market
The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
Next catalyst
None dated

What to watchThe REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau Medical announced updated interim results from its REGAIN trial of Alpha DaRT for recurrent glioblastoma, showing all eight treated patients alive, 100% objective response rate in evaluable patients (83.3% complete responses), and no unanticipated serious adverse events. The data were presented at the SNO annual meeting and suggest strong early efficacy in a devastating cancer with an average survival of 8 months.

Key Facts

  • All eight treated patients alive as of November 11, 2026; median overall survival not reached
  • Six evaluable patients: 100% objective response rate (5 complete responses, 1 partial response)
  • No unanticipated serious adverse events; primary feasibility and safety endpoints met
  • Trial enrolling toward 20 patients; initial discussions suggest data may support market submission
  • Company has marketing approval in Japan for head and neck cancer and in Israel for SCC of skin and oral cavity

Financial Impact

Alpha Tau market cap is $1.2B; positive interim data in a high-unmet-need indication could significantly increase the probability of regulatory approval and commercial value, though no revenue or deal figures are stated.

probability of regulatory approvalfuture revenue potential

Risk Factors

  • Asymptomatic radiation necrosis observed in four patients; follow-up scans needed to distinguish from tumor progression
  • Small sample size (8 patients, 6 evaluable); results may not replicate in larger cohort
  • Alpha DaRT not yet approved for glioblastoma; regulatory pathway uncertain
  • Company has limited operating history and has incurred significant losses

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3403120

Track record

25 reports on DRTS

Performance horizon

9 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
  3. Nov 15, 20261d ago Press Release Bullish 7/10 Viewing Entry $13.35 Now $11.97 −10.34% settles Feb 12
  4. Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
  5. Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
  6. Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
  7. Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
  8. Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
  9. Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
  10. Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
Showing 10 of 25

US Market Status

Market Closed · Opens in 8h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 15, 2026